Compare
Corcept Therapeutics vs Merck & (CORT vs MRK)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Corcept Therapeutics (CORT) returned -5.1% and Merck & (MRK) +73.9%; so far this year the figures are +109.1% and +39.4%.
Merck & is the larger company by market value, about 45.4 times the size of Corcept Therapeutics.
On trailing earnings, CORT trades at 57.3 times and MRK at 149.7 times.
Revenue grew +30.0% at CORT and +4.9% at MRK over the last year.
CORT pays no dividend. MRK yields 2.32%.
Data as of the latest close. Not investment advice.
Relative performance
| CORT | MRK | |
|---|---|---|
| Price | $72.77 | $146.73 |
| 1-day | +1.59% | -0.14% |
| YTD | +109.11% | +39.40% |
| 1 year | -5.06% | +73.87% |
| 3 years | +159.06% | +42.66% |
| Market cap | $8.0B | $361.7B |
| P/E | 57.3 | 149.7 |
| P/S | 8.26 | 5.37 |
| P/B | 9.55 | 8.06 |
| Revenue growth | +30.00% | +4.90% |
| EPS growth | +46.00% | -87.10% |
| Gross margin % | 98.5 | 71.8 |
| Net margin % | 16.8 | 3.6 |
| ROE % | 19.5 | 5.5 |
| Debt / equity | 0.00 | 1.20 |
| FCF yield % | 2.4 | 4.1 |
| Dividend yield % | — | 2.32 |
| Beta | 1.96 | 0.18 |
| RSI (14) | 22.0 | 51.3 |
| Technical rating |